EGFR Inhibitors-Induced Skin Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major EGFR inhibitors-induced skin disorders markets are expected to exhibit a CAGR of 17.89% during 2024-2034.
The EGFR inhibitors-induced skin disorders market has been comprehensively analyzed in IMARC's new report titled "EGFR Inhibitors-Induced Skin Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". EGFR (epidermal growth factor receptor) inhibitors-induced skin disorders refer to a group of adverse skin reactions that can occur as a result of treatment with EGFR inhibitors. These ailments can occur within days to weeks after starting EGFR inhibitor therapy and can vary in severity. EGFR inhibitors are a class of targeted cancer therapies that work by blocking the activity of the EGFR protein, which can disrupt the normal balance of skin cell growth, leading to the observed skin toxicities. Common symptoms associated with the ailments include rash, dry and itchy skin, discomfort, irritation, skin flaking and peeling, changes in the appearance of the nails, altered hair growth, etc. These skin reactions can significantly impact the patient's quality of life and might even lead to dose adjustments or treatment interruptions if they become severe. Diagnosing EGFR inhibitors-induced skin disorders involves a combination of clinical evaluation, patient history, and sometimes additional tests.
The increasing cases of oncological disease that require treatment with EGFR inhibitors, which can cause disruption in the signaling pathways, leading to abnormal cell behavior in the skin, are primarily driving the EGFR inhibitors-induced skin disorders market. In addition to this, the inflating utilization of specialized topical treatments, such as corticosteroids and antibiotics, to mitigate inflammatory responses and infection risks associated with skin reactions is also creating a positive outlook for the market. Moreover, the widespread adoption of laser therapies, since they work by targeting and treating the symptomatic skin areas to provide rapid relief and a healthier skin appearance, is further bolstering the market growth. Apart from this, the rising usage of targeted therapies, which specifically address the cellular pathways disturbed by EGFR inhibitors, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of dermatological consultations and interventions, as they aid in early diagnosis, effective management, and mitigation of these skin-related side effects in individuals suffering from the ailments, is also augmenting the market growth. Furthermore, the escalating application of personalized medicine, concentrating on minimizing adverse reactions while maximizing therapeutic efficacy, is expected to drive the EGFR inhibitors-induced skin disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the EGFR inhibitors-induced skin disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for EGFR inhibitors-induced skin disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the EGFR inhibitors-induced skin disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the EGFR inhibitors-induced skin disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the EGFR inhibitors-induced skin disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current EGFR inhibitors-induced skin disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the EGFR inhibitors-induced skin disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the EGFR inhibitors-induced skin disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the EGFR inhibitors-induced skin disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with EGFR inhibitors-induced skin disorders across the seven major markets?
What is the size of the EGFR inhibitors-induced skin disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of EGFR inhibitors-induced skin disorders?
What will be the growth rate of patients across the seven major markets?
EGFR Inhibitors-Induced Skin Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for EGFR inhibitors-induced skin disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the EGFR inhibitors-induced skin disorders market?
What are the key regulatory events related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by status related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by phase related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by route of administration related to the EGFR inhibitors-induced skin disorders market?
The EGFR inhibitors-induced skin disorders market has been comprehensively analyzed in IMARC's new report titled "EGFR Inhibitors-Induced Skin Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". EGFR (epidermal growth factor receptor) inhibitors-induced skin disorders refer to a group of adverse skin reactions that can occur as a result of treatment with EGFR inhibitors. These ailments can occur within days to weeks after starting EGFR inhibitor therapy and can vary in severity. EGFR inhibitors are a class of targeted cancer therapies that work by blocking the activity of the EGFR protein, which can disrupt the normal balance of skin cell growth, leading to the observed skin toxicities. Common symptoms associated with the ailments include rash, dry and itchy skin, discomfort, irritation, skin flaking and peeling, changes in the appearance of the nails, altered hair growth, etc. These skin reactions can significantly impact the patient's quality of life and might even lead to dose adjustments or treatment interruptions if they become severe. Diagnosing EGFR inhibitors-induced skin disorders involves a combination of clinical evaluation, patient history, and sometimes additional tests.
The increasing cases of oncological disease that require treatment with EGFR inhibitors, which can cause disruption in the signaling pathways, leading to abnormal cell behavior in the skin, are primarily driving the EGFR inhibitors-induced skin disorders market. In addition to this, the inflating utilization of specialized topical treatments, such as corticosteroids and antibiotics, to mitigate inflammatory responses and infection risks associated with skin reactions is also creating a positive outlook for the market. Moreover, the widespread adoption of laser therapies, since they work by targeting and treating the symptomatic skin areas to provide rapid relief and a healthier skin appearance, is further bolstering the market growth. Apart from this, the rising usage of targeted therapies, which specifically address the cellular pathways disturbed by EGFR inhibitors, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of dermatological consultations and interventions, as they aid in early diagnosis, effective management, and mitigation of these skin-related side effects in individuals suffering from the ailments, is also augmenting the market growth. Furthermore, the escalating application of personalized medicine, concentrating on minimizing adverse reactions while maximizing therapeutic efficacy, is expected to drive the EGFR inhibitors-induced skin disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the EGFR inhibitors-induced skin disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for EGFR inhibitors-induced skin disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the EGFR inhibitors-induced skin disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the EGFR inhibitors-induced skin disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the EGFR inhibitors-induced skin disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current EGFR inhibitors-induced skin disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the EGFR inhibitors-induced skin disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the EGFR inhibitors-induced skin disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the EGFR inhibitors-induced skin disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of EGFR inhibitors-induced skin disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with EGFR inhibitors-induced skin disorders across the seven major markets?
What is the size of the EGFR inhibitors-induced skin disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of EGFR inhibitors-induced skin disorders?
What will be the growth rate of patients across the seven major markets?
EGFR Inhibitors-Induced Skin Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for EGFR inhibitors-induced skin disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the EGFR inhibitors-induced skin disorders market?
What are the key regulatory events related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by status related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by phase related to the EGFR inhibitors-induced skin disorders market?
What is the structure of clinical trial landscape by route of administration related to the EGFR inhibitors-induced skin disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EGFR INHIBITORS-INDUCED SKIN DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EGFR INHIBITORS-INDUCED SKIN DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EGFR INHIBITORS-INDUCED SKIN DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 EGFR INHIBITORS-INDUCED SKIN DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EGFR INHIBITORS-INDUCED SKIN DISORDERS - UNMET NEEDS
10 EGFR INHIBITORS-INDUCED SKIN DISORDERS - KEY ENDPOINTS OF TREATMENT
11 EGFR INHIBITORS-INDUCED SKIN DISORDERS - MARKETED PRODUCTS
11.1 List of EGFR Inhibitors-Induced Skin Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EGFR INHIBITORS-INDUCED SKIN DISORDERS - PIPELINE DRUGS
12.1 List of EGFR Inhibitors-Induced Skin Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. EGFR INHIBITORS-INDUCED SKIN DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EGFR INHIBITORS-INDUCED SKIN DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EGFR INHIBITORS-INDUCED SKIN DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
16 EGFR INHIBITORS-INDUCED SKIN DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EGFR INHIBITORS-INDUCED SKIN DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EGFR INHIBITORS-INDUCED SKIN DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EGFR INHIBITORS-INDUCED SKIN DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EGFR INHIBITORS-INDUCED SKIN DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EGFR INHIBITORS-INDUCED SKIN DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 EGFR INHIBITORS-INDUCED SKIN DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EGFR INHIBITORS-INDUCED SKIN DISORDERS - UNMET NEEDS
10 EGFR INHIBITORS-INDUCED SKIN DISORDERS - KEY ENDPOINTS OF TREATMENT
11 EGFR INHIBITORS-INDUCED SKIN DISORDERS - MARKETED PRODUCTS
11.1 List of EGFR Inhibitors-Induced Skin Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EGFR INHIBITORS-INDUCED SKIN DISORDERS - PIPELINE DRUGS
12.1 List of EGFR Inhibitors-Induced Skin Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. EGFR INHIBITORS-INDUCED SKIN DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EGFR INHIBITORS-INDUCED SKIN DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EGFR INHIBITORS-INDUCED SKIN DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 EGFR Inhibitors-Induced Skin Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 EGFR Inhibitors-Induced Skin Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 EGFR Inhibitors-Induced Skin Disorders - Access and Reimbursement Overview
16 EGFR INHIBITORS-INDUCED SKIN DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EGFR INHIBITORS-INDUCED SKIN DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EGFR INHIBITORS-INDUCED SKIN DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
